{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Talazoparib in Advanced Breast Cancer With a Germline BRCA Mutation
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
Method of Participation in the Learning Process/Evaluation Method Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form. Getting the Most out of the Activity As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.Accreditation Statement:
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Purpose of Activity
To provide information on the results of the EMBRACA Phase 3 study evaluating the use of talazoparib in advanced breast cancer patients with a germline BRCA mutation.Learning Objectives
After completing this continuing education activity you will be able to:
- Summarize the purpose and design of the EMBRACA phase 3 evaluation of talazoparib in advanced breast cancer patients with a germline BRCA mutation.
- Outline the findings and implications of this study.
Disclosures
The author, faculty, staff, and planners have no financial relationships with any ineligible organizations regarding this educational activity.
Price:
$10.00
Credits:
- ACPE 1.0 CH
- ACCME 1.0 CME
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. UAN# 0431-0000-22-021-H04-P
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Pharmacist
Test Code: OT0219PH
Published: April 2019
Expires: 9/13/2025
Sources:
Allied Health Collection
Required Passing Score: 8/10 (80%)